What's Happening?
Exact Imaging has announced results from the OPTIMUM clinical trial, demonstrating that its ExactVu micro-ultrasound platform is non-inferior to MRI fusion-guided biopsy for diagnosing prostate cancer.
The trial involved 802 biopsy-naive men across 20 centers and eight countries. The study's findings, presented at the European Multidisciplinary Congress on Urological Cancers, suggest that ExactVu could serve as an alternative to MRI for image-guided prostate biopsy. The technology offers an affordable, in-office diagnostic tool that speeds up the diagnosis process, potentially improving standard care and reducing disparities.
Why It's Important?
The trial results highlight the transformative potential of micro-ultrasound technology in prostate cancer diagnosis. By providing a cost-effective and accessible alternative to MRI, ExactVu can enhance diagnostic capabilities for urologists and patients, particularly in areas with limited access to MRI. This advancement may lead to improved patient outcomes and more equitable healthcare delivery. As the technology gains validation, it could become a standard tool in urological practices, supporting a wide range of clinical applications from active surveillance to surgical planning.
